Recruiting

Observational StudyConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)

Sponsor:

Alnylam Pharmaceuticals

Code:

NCT04561518

Conditions

Transthyretin-Mediated Amyloidosis

ATTR Amyloidosis

Eligibility Criteria

Sex: All

Age: 0+

Healthy Volunteers: Not accepted

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-08-26. This information was provided to ClinicalTrials.gov by Alnylam Pharmaceuticals on 2026-05-29.